Cystic fibrosis-related diabetes

Cystic fibrosis-related diabetes is a specific type of diabetes that develops in the setting of cystic fibrosis and is not equivalent to either type 1 or type 2 diabetes mellitus. It is a distinct metabolic condition characterized primarily by a progressive defect in insulin secretion caused by the pancreatic injury typical of the disease, upon which chronic inflammation, recurrent respiratory infections, corticosteroid therapy, catabolic stress, and periods of increased insulin resistance may be superimposed to varying degrees. Its clinical importance is considerable because it is not merely a biochemical complication of cystic fibrosis, but an event capable of worsening nutritional status, lung function, the frequency of infectious exacerbations, and overall prognosis.

From a nosologic standpoint, Cystic Fibrosis-Related Diabetes (CFRD) belongs to the other specific types of diabetes and is the most typical model of diabetes secondary to a multisystem genetic disease. Its distinctive feature is that hyperglycemia develops in an organism whose energy metabolism is already under pressure from malabsorption, increased energy expenditure, chronic respiratory inflammation, and frequent impairment of the exocrine pancreas. The resulting metabolic picture differs both from beta-cell autoimmunity in type 1 diabetes and from the insulin-resistant metabolic syndrome of type 2 diabetes. For this reason, CFRD requires its own criteria for suspicion, screening, clinical interpretation, and treatment, without classificatory shortcuts.

Cystic fibrosis-related diabetes is now regarded as the most common extrapulmonary comorbidity of cystic fibrosis, and its frequency rises progressively with age. Guidelines from the Cystic Fibrosis Foundation report that CFRD affects up to 20% of adolescents and up to 50% of adults with cystic fibrosis, while the foundation’s more recent 2024 registry data show that 24% of people with cystic fibrosis had diabetes related to the disease, with a much smaller proportion classified as having type 1 or type 2 diabetes. These figures clearly demonstrate that the problem is not marginal, but structural to the natural history of cystic fibrosis.

The age-related increase in prevalence reflects the progressive destruction and disorganization of the pancreas over the course of the disease. Overt diabetes is less common in young children, but impaired glucose tolerance, postprandial glucose excursions, or intermittent hyperglycemia during infections, respiratory exacerbations, or glucocorticoid therapy may already occur in childhood. During adolescence and young adulthood, these abnormalities become more frequent and may progress to sustained diabetes. This progressive course is one of the most characteristic features of CFRD and explains the need for systematic screening even in asymptomatic patients.

The modern epidemiology of CFRD is also influenced by two major changes. The first is improved survival among people with cystic fibrosis, which increases the number of individuals who live long enough to develop disorders of glucose metabolism. The second is the introduction of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, which are profoundly changing the course of the disease. At present, however, available evidence is not sufficient to abolish or reduce standard CFRD screening, because the potential metabolic benefit of modulators appears to vary among patients and has not yet definitively rewritten the natural history of diabetes associated with cystic fibrosis.

Clinical practice also faces a problem of underestimation. Some CFRD may remain clinically silent in its early stages, precisely while it begins to exert adverse effects on weight, lean mass, and respiratory function. Epidemiology based solely on symptomatic diagnoses therefore fails to capture the full spectrum of dysglycemia associated with cystic fibrosis. In other words, CFRD is relevant not only because of the number of patients who formally receive the diagnosis, but also because many pass through a continuum of glycemic dysfunction that may already have clinical consequences before full nosographic criteria are met.

The pathophysiology of cystic fibrosis-related diabetes is complex and cannot be reduced to a single traditional diabetes category. The dominant defect is progressive insulin deficiency, caused primarily by structural pancreatic injury. From the earliest stages of life, the pancreas in cystic fibrosis is exposed to viscous secretions, ductal obstruction, inflammation, fibrosis, and fatty replacement of the parenchyma. This process profoundly disrupts the relationship between the exocrine and endocrine compartments, reduces the mass and functional efficiency of pancreatic islets, and impairs the beta cell’s ability to respond appropriately to a glucose load.

CFRD, however, is not simply a replica of absolute insulin-deficient diabetes. Insulin secretion is often still present, especially in the early stages, but is delayed, quantitatively inadequate, and poorly synchronized with meals. Loss of the early postprandial insulin peak is a particularly important pathophysiologic feature because it promotes post-meal hyperglycemia even while fasting glucose remains normal. This explains why the disease may escape simplified assessments in its early stages and why the OGTT retains a central role in screening.

Alongside the secretory defect, a variable degree of insulin resistance is present. In CFRD, this is not usually constitutive as it is in type 2 diabetes mellitus, but fluctuates with the clinical condition. Respiratory infections, pulmonary exacerbations, systemic inflammation, glucocorticoid use, acute stress, enteral feeding, and puberty can temporarily increase insulin requirements. The result is a dynamic metabolic profile in which a patient may shift from relative stability to marked hyperglycemia during exacerbations. The combination of limited beta-cell reserve and fluctuating insulin requirements is one of the reasons for the metabolic fragility typical of CFRD.

Another relevant pathophysiologic feature is the close relationship between nutritional status and glucose metabolism. Insulin acts not only as an antihyperglycemic hormone, but also as an essential anabolic signal for maintaining lean mass, protein synthesis, and energy balance. In cystic fibrosis, where the patient already lives in a precarious balance among increased energy expenditure, malabsorption, and chronic inflammation, reduced insulin action has a particularly severe effect on body weight, growth, and muscle strength. This explains why CFRD can worsen lung function and nutrition even before classic symptoms of diabetes appear.

The direct role of CFTR dysfunction in beta cells and other endocrine tissues remains under investigation, but current understanding is that structural pancreatic injury is the principal mechanism, while intrinsic cellular, inflammatory, and microenvironmental factors may further contribute to secretory dysfunction. Incretin physiology, hepatic metabolism, and intestinal absorption may also be altered. CFRD should therefore be understood as a disease at the interface of endocrinology, pulmonology, gastroenterology, and clinical nutrition, in which elevated blood glucose is the endpoint of a prolonged trajectory of pancreatic remodeling and chronic systemic stress.

The clinical manifestations of cystic fibrosis-related diabetes are often less conspicuous than those of classic forms of diabetes. Onset may be gradual and remain silent for a long time, which is why the disease is often detected through screening before polyuria, polydipsia, or overt weight loss develops. In practice, the first sign is not always explicit diabetic symptoms, but deterioration in the clinical trajectory of cystic fibrosis: weight loss, growth arrest, loss of muscle mass, declining respiratory function, more frequent pulmonary exacerbations, or slower recovery after infections.

From a history-taking standpoint, it is therefore essential not to focus only on classic symptoms of diabetes, but also to look for indirect signs of insulin-deficient catabolism. An adolescent or young adult with cystic fibrosis who loses weight despite an adequate caloric intake, shows declining respiratory performance, or has increasing difficulty maintaining nutritional status may be in the early stages of CFRD even without an overt polyuria-polydipsia syndrome. This feature makes the clinical picture insidious and explains why annual screening is necessary even in apparently stable individuals.

As diabetes becomes more evident, typical metabolic symptoms such as polyuria, polydipsia, fatigue, and weight loss may appear. Diabetic ketoacidosis is much less common than in type 1 diabetes mellitus, however, because some endogenous insulin production usually persists. This has important clinical implications: the absence of ketoacidosis should neither be reassuring nor lead to underestimation of the problem. CFRD can cause clinically significant harm even without the dramatic manifestations of classic autoimmune diabetes.

The physical examination must be interpreted in the context of cystic fibrosis. The clinician may find a low body mass index, reduced muscle mass, delayed puberty or growth in younger patients, previously recognized signs of exocrine pancreatic insufficiency, and respiratory findings related to chronic lung disease. In many cases, the examination does not reveal “specific” signs of diabetes, but rather an overall deterioration in clinical status. This nonspecific presentation makes an integrated interpretation of the patient’s history essential.

Special situations warrant separate consideration, including infectious exacerbations, glucocorticoid therapy, nocturnal enteral feeding, and pregnancy in women with cystic fibrosis. In these settings, intermittent or situational hyperglycemia may emerge before or alongside overt CFRD. Even when blood glucose subsequently improves, these abnormalities should not be dismissed as merely transient, because they often belong to the evolving continuum of cystic fibrosis-related diabetes and require specialist interpretation.

In a patient with cystic fibrosis, suspicion of CFRD should remain constant from the age at which routine screening begins, even in the absence of symptoms. There are, however, situations in which suspicion should become more immediate and intense. The first is unexplained deterioration in weight, nutritional status, or respiratory function. The second is the occurrence of hyperglycemia during pulmonary exacerbations, courses of intravenous antibiotics, systemic glucocorticoid therapy, or gastrostomy feeding. The third is the presence of classic symptoms of diabetes, although this is a less common initial presentation in cystic fibrosis.

Suspicion should be particularly strong in individuals with marked exocrine pancreatic insufficiency, long disease duration, adolescence or adulthood, and progressive nutritional vulnerability. A normal fasting glucose does not exclude the problem, because early abnormalities may be predominantly postprandial. It is therefore incorrect to rely solely on occasional glucose measurements or glycated hemoglobin. CFRD should be suspected as a progressive postprandial disorder even before fasting diabetes becomes established.

Pregnancy is another setting that requires consideration. In women with cystic fibrosis, the physiologic increase in insulin resistance during gestation is superimposed on reduced beta-cell reserve, facilitating the emergence of hyperglycemia. Assessment should follow obstetric criteria for gestational diabetes, but the finding remains highly clinically relevant because it may reveal broader underlying metabolic vulnerability. Similarly, a patient receiving nocturnal enteral feeding may have hyperglycemia predominantly during the infusion period, requiring specific attention rather than dismissal as a merely technical fluctuation.

In practice, CFRD should be suspected not only when diabetes appears, but whenever a patient with cystic fibrosis shows signs of loss of anabolic balance or hyperglycemia during clinically stressful circumstances. This approach is crucial because it allows the disease to be understood dynamically and detected before nutritional and respiratory deterioration becomes more difficult to reverse.

The diagnosis of cystic fibrosis-related diabetes is based on the general criteria for diabetes, with several important operational distinctions. According to guidelines from the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the Cystic Fibrosis Foundation, the reference screening method remains an annual 2-hour OGTT, beginning at 10 years of age. This is because CFRD is often characterized by early postprandial hyperglycemia while fasting glucose remains normal, a situation in which simpler tools may lack diagnostic sensitivity.

According to ISPAD guidelines, onset of CFRD is defined as the first time a person with cystic fibrosis meets diagnostic criteria for diabetes, even if glucose tolerance subsequently appears to improve temporarily. This concept has strong clinical value because it recognizes the fluctuating yet progressive nature of the disorder and prevents early phases of documented hyperglycemia from being dismissed as irrelevant. In cystic fibrosis, metabolic abnormalities may vary in the short term while still retaining long-term prognostic significance.

The practical diagnostic sequence begins with annual OGTT screening in asymptomatic individuals. If the test documents glucose values diagnostic of diabetes, the diagnosis is made according to standard criteria. During acute illness, systemic glucocorticoid use, or nocturnal enteral feeding, the diagnosis may also be established on the basis of persistent glycemic patterns in those specific settings. ISPAD guidelines indicate, for example, that during exacerbations or steroid therapy, diabetes may be diagnosed when fasting glucose values of at least 126 mg/dL or 2-hour postprandial glucose values of at least 200 mg/dL persist for more than 48 hours.

Glycated hemoglobin has a more limited role in CFRD screening than in other forms of diabetes because it may be falsely reassuring in the early stages. Continuous glucose monitoring (CGM) and other continuous-monitoring tools are becoming increasingly relevant in clinical practice and research, particularly for identifying intermittent hyperglycemia and gaining a better understanding of the patient’s glycemic profile, but they do not currently replace the OGTT as the standard screening test. They can, however, usefully complement assessment in equivocal cases, in patients with an established diagnosis, or in particular clinical settings.

The differential diagnosis primarily includes type 1 and type 2 diabetes mellitus. Type 1 diabetes is less likely in the absence of autoantibodies, ketosis, and abrupt absolute insulin deficiency, whereas type 2 diabetes is less consistent in the absence of visceral obesity and marked metabolic syndrome. Coexistence is nevertheless possible, so automatic assumptions must be avoided. In a patient with cystic fibrosis and hyperglycemia, the main issue is to determine whether the patient has CFRD as an expression of the underlying disease, a different form of diabetes, or a combination of contributing factors.

Cystic fibrosis-related diabetes is not a uniform category, but a continuum of glucose-metabolism abnormalities ranging from the earliest postprandial disturbances to overt diabetes. The most useful classification therefore integrates the clinical finding, pathophysiologic context, and mode of onset of hyperglycemia. The objective is not to invent new independent labels, but to characterize the different forms of CFRD presentation accurately because they have different implications for screening, treatment, and follow-up.

Main clinical presentations of CFRD

• Asymptomatic CFRD identified through screening: the most typical form, detected by annual OGTT before obvious diabetic symptoms appear.
• CFRD emerging during clinical stress: develops or becomes manifest during infections, steroid therapy, hospitalization, or enteral feeding.
• CFRD with nutritional and respiratory impact: associated with weight loss, declining lung function, and greater clinical instability.
• CFRD in special settings: pregnancy, nocturnal enteral feeding, the post-exacerbation period, or other conditions that alter insulin balance.

From a more strictly pathophysiologic perspective, CFRD can be understood as the result of progressive beta-cell insufficiency modulated by intercurrent factors. Early stages are dominated by loss of early insulin secretion and postprandial hyperglycemia. At later stages, fasting hyperglycemia and a more sustained diabetic state may also develop. This progression is not linear in every patient, but the general principle remains valid and explains why diagnosis does not coincide with an abrupt transition from health to disease, but rather with the clinical emergence of a biological process that has been evolving for some time.

Classification also has prognostic significance. Forms identified early may allow more timely nutritional and insulin interventions. Forms that emerge during exacerbations or steroid therapy indicate more fragile endocrine reserve. Forms with an evident effect on growth, weight, and respiratory function show that the disease has already crossed the threshold of a laboratory abnormality alone. In this sense, classifying CFRD primarily means understanding where the patient lies along the metabolic trajectory of cystic fibrosis.

Treatment of cystic fibrosis-related diabetes follows a different rationale from that of common type 2 diabetes mellitus. The goal is not merely to reduce hyperglycemia, but to restore, as far as possible, a metabolic balance favorable to nutrition, lean mass, and respiratory function. Guidelines therefore identify insulin as the treatment of choice for CFRD. Insulin corrects the dominant pathophysiologic defect—relative or progressive deficiency of insulin secretion—and simultaneously provides an anabolic effect that is essential in a patient exposed to chronic catabolism.

Insulin therapy should be individualized according to the patient’s glycemic pattern. In some individuals, predominantly prandial support is initially sufficient, particularly when postprandial hyperglycemia is the main problem. Others require a more complete basal-bolus regimen. Patients receiving nocturnal enteral feeding or those with marked metabolic variability may require dedicated strategies, including pump therapy or regimens tailored to feeding schedules. The principle remains the same: adapt therapy to the patient’s actual clinical profile rather than forcing the patient into standardized regimens designed for other forms of diabetes.

Noninsulin glucose-lowering medications are not the standard first-line treatment for CFRD. The rationale is not merely regulatory, but pathophysiologic: the dominant problem is insulin deficiency in a catabolic setting, and a patient with cystic fibrosis does not benefit from approaches that risk delaying adequate anabolic therapy. Strategies other than insulin have been studied in selected settings, but their role remains far more limited and does not replace the guideline-recommended approach.

Nutritional therapy in CFRD differs fundamentally from the usual approach to type 2 diabetes mellitus. Routine caloric or weight restriction is not pursued in cystic fibrosis; the aim is to preserve or improve nutritional status through adequate energy and protein intake. Therapeutic education must therefore prevent common conceptual errors, such as inappropriate calorie reduction to “treat diabetes,” which can worsen body mass and respiratory outcomes in these patients. Correct treatment integrates insulin, adequate nutrition, and comprehensive cystic fibrosis care.

Treatment with CFTR modulators also warrants attention. Recent data suggest that these medications may improve some aspects of glucose metabolism in certain patients, but the effect is neither uniform nor predictable enough to justify abandoning diabetes surveillance. Clinicians should therefore regard modulators as part of the overall improvement in the underlying disease, not as substitutes for specific CFRD management.

Follow-up of cystic fibrosis-related diabetes should be built around a dual rationale. Glycemic control must be monitored with appropriate diabetes tools, while weight, body composition, growth, lung function, infection frequency, and quality of life must also be followed closely. In CFRD, the value of monitoring lies not only in preventing microvascular complications, but also in determining whether therapy is genuinely improving the patient’s anabolic and respiratory balance.

Metabolic monitoring includes capillary glucose measurements, glycated hemoglobin, possible use of CGM, review of insulin therapy, and attention to hypoglycemia. Hypoglycemia should not be underestimated, especially in individuals with variable food intake, irregular physical activity, or periods of intercurrent illness. Continuous monitoring systems may be particularly useful in younger patients, in cases of marked glycemic variability, and when glucose trends need to be correlated with meals, infections, or enteral feeding.

Follow-up must also integrate the overall course of cystic fibrosis. An improvement in glucose values that is not accompanied by weight recovery, respiratory stabilization, or good treatment tolerability cannot be considered fully satisfactory. Similarly, deterioration in respiratory or nutritional status should prompt reassessment of glycemic control because the two are closely intertwined. Effective follow-up in CFRD is therefore always an endocrine-respiratory-nutritional assessment, even when formally conducted in a single clinic.

With regard to chronic diabetic complications, available evidence indicates that microvascular complications may also develop in CFRD, although their frequency and profile may differ from those in other forms of diabetes. Particularly in people with a longer known disease duration, follow-up should therefore include surveillance for retinopathy, nephropathy, and neuropathy according to recommendations applicable to the individual patient. The relative rarity of macrovascular events compared with type 2 diabetes does not justify neglecting comprehensive surveillance.

The prognosis of cystic fibrosis-related diabetes is closely linked to the timing of diagnosis and the quality of care. Historically, CFRD was associated with deteriorating nutritional status, declining lung function, and reduced survival. Guidelines and large cohorts have clearly shown that a diagnosis of CFRD is not a neutral finding, but a clinical turning point in the history of cystic fibrosis. Prognosis therefore improves when the disease is identified early and treated in a manner consistent with its pathophysiology.

Part of the prognostic improvement observed in recent years reflects the overall evolution of cystic fibrosis care, including CFTR modulators, improved nutrition, more effective infection control, and increasing multidisciplinary integration. CFRD nevertheless remains a comorbidity of major clinical importance and cannot be regarded as a mere laboratory epiphenomenon. Its presence signals more complex disease, greater metabolic vulnerability, and a need for closer surveillance.

From a strictly diabetologic perspective, prognosis depends on the ability to maintain glycemic control compatible with good nutrition and a low risk of hypoglycemia. From a systemic perspective, it depends on preserving growth, lean mass, quality of life, and respiratory function. The true prognosis of CFRD is therefore always multidimensional: it is not defined solely by the glycated hemoglobin value, but by the interaction among metabolic control, nutritional trajectory, and the course of lung disease.

In summary, cystic fibrosis-related diabetes is a condition whose prognosis can be significantly modified by early diagnosis, appropriate screening, proper use of insulin, and integrated follow-up. The true prognostic error is not only treating diabetes poorly, but failing to recognize that hyperglycemia in a patient with cystic fibrosis is often a marker of loss of overall clinical balance.